Urinary tract infection

Pubic hair: beyond brazilians, more than manscaping

Retrieved on: 
Wednesday, April 10, 2024
Research, Health, Urinary tract infection, Gas, Vibration, Hair loss, Friction, Pressure, Facial expression, Science, Risk, Perspiration, Observation, Partner (business rank), Bacteria, Pheromone, Human, Woman, Body image, Sensation, Urine, Infection, Skin, Eyebrow, Scalp, Gland, Ammonia, Urea, Animal, Emotion

So, what about pubic hair?

Key Points: 
  • So, what about pubic hair?
  • Let’s talk about sex
    Much of the effort that goes into shaping or removing pubic hair also shapes and defines sexual identities.
  • While the properties of pheromones are not as well established in humans, there’s speculation that pubic hair plays a significant role.
  • Pubic hair grooming has been associated with an increased risk of genital infections but this has also been refuted.

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
Wednesday, April 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Symantec Endpoint Protection, Prejudice, SPA, Patient, CRL, NDA, G&A, CMC, Disclosure, Insurance, Senior, Woman, Investment, Infection, Therapy, Urinary tract infection, ATM, FDA, ITRM, Food, Pharmaceutical industry

DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Iterum reported positive top-line data in January 2024 and plans to resubmit its NDA early in the second quarter of 2024.
  • In connection with this strategic process, Iterum has engaged a financial advisor to assist management and the board in evaluating strategic alternatives.
  • In addition, during the fourth quarter of 2022, a change in the discount rate impacted the fair value of the Royalty-Linked Notes.
  • Iterum will host a conference call today, Thursday, March 28, 2024 at 8:30 a.m. Eastern Time.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

NanoVibronix Issues Letter to Stockholders

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, National Health Service, Growth, Partnership, COVID-19, Patient, SAW, Gold, NHS, University, University of Michigan, Quality of life, Insurance, GSA, Urinary tract infection, Pain, Medicare, FDA, CMS, Engineering, Food, Pharmaceutical industry

We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.

Key Points: 
  • We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
  • A driving factor in our increased revenues was increased sales to customers using the Veterans’ Health System and worker’s compensation plans.
  • On our balance sheet for the period ended December 31, 2023, we had $3.3 million of cash and inventory of $2.7 million.
  • CMS invited NanoVibronix to a public meeting to present its findings and to answer CMS’s questions, which was held June 1, 2023.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

INDUSTRY LEADING PPA EFPGA AND DSP/AI IN DEVELOPMENT FOR TSMC N5/4/3

Retrieved on: 
Tuesday, April 9, 2024
Pixel, DSP, GPIO, Inference, IPS, Complex, Urinary tract infection, FFT, Field-programmable gate array, Silicon, Architecture, Graphics processing unit, SDR, IP, FPGA, TSMC

MOUNTAIN VIEW, Calif., April 9, 2024 /PRNewswire/ -- Flex Logix® Technologies, Inc., the leading supplier of embedded FPGA (eFPGA) IP and reconfigurable DSP/AI solutions, announced that it is in development of next generation EFLX eFPGA Generation 3.0 for TSMC N5/4 and N3. EFLX Generation 3.0, along with the eXpreso™ eFPGA compiler enables Millions of LUTs and higher frequency operation; and LUTs that can programmably be I/O's for applications requiring a lot of control like networking switches or InferX DSP/SDR/AI. EFLX Gen3.0 can reconfigure in a few microseconds for dynamic workload switches.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 9, 2024 /PRNewswire/ -- Flex Logix® Technologies, Inc. , the leading supplier of embedded FPGA (eFPGA) IP and reconfigurable DSP/AI solutions, announced that it is in development of next generation EFLX eFPGA Generation 3.0 for TSMC N5/4 and N3.
  • EFLX Generation 3.0, along with the eXpreso™ eFPGA compiler enables Millions of LUTs and higher frequency operation; and LUTs that can programmably be I/O's for applications requiring a lot of control like networking switches or InferX DSP/SDR/AI.
  • "Our commercial customers rely on our TSMC EFLX eFPGA technology already from 40nm to 7nm for applications including reconfigurable crypto agility, micro FPGA, programmable GPIO, customer-programmable accelerators, reconfigurable packet processing, asynchronous control and many more.
  • We are now supporting our customers on TSMC N5/4/3 with our improved EFLX architecture and our new InferX DSP/AI hardware and the InferX compiler.

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.